BioMarin Pharmaceutical Inc. (BMRN) Financial Statements

Executive TeamFinancials
SegmentsShareholders

BioMarin Pharmaceutical financial statements at a glance

BioMarin Pharmaceutical reported revenue of $3.22 billion for fiscal year 2025 (ended December 31, 2025), up 12.9% from fiscal year 2024. Net income was $348.90 million, a net margin of 10.8%, and diluted earnings per share were $1.80.

At the end of fiscal year 2025 it had total assets of $7.59 billion, total liabilities of $1.51 billion and shareholders' equity of $6.09 billion, with cash and short-term investments of $1.56 billion and total debt of $605.86 million.

Its operations brought in $827.99 million of cash; capital spending was $110.98 million, leaving free cash flow of $717.02 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

BMRN logo

BioMarin Pharmaceutical Inc.

BMRNUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
3.22B
Prev Year: 2.85B
YoY: +12.9%
Operating Revenue
3.22B
Prev Year: 2.85B
YoY: +12.9%
Total Expenses
2.81B
Prev Year: 2.38B
YoY: +18.2%
Total Operating Income as Reported
409.48M
Prev Year: 484.21M
YoY: -15.4%
Diluted NI Available to Com Stockholders
356.24M
Prev Year: 434.19M
YoY: -18.0%
Average Dilution Earnings
7.33M
Prev Year: 7.33M
YoY: +0.1%
Cost of Revenue
717.44M
Prev Year: 580.24M
YoY: +23.6%
Gross Profit
2.50B
Prev Year: 2.27B
YoY: +10.1%
Operating Expense
2.09B
Prev Year: 1.80B
YoY: +16.4%
Selling General and Administrative
1.15B
Prev Year: 1.01B
YoY: +14.3%
General and Administrative Expense
622.80M
Prev Year: 532.30M
YoY: +17.0%
Other General and Administrative
622.80M
Prev Year: 532.30M
YoY: +17.0%
Selling and Marketing Expense
530.20M
Prev Year: 476.70M
YoY: +11.2%
Research and Development
921.93M
Prev Year: 747.18M
YoY: +23.4%
Depreciation Amortization Depletion
19.39M
Prev Year: 43.30M
YoY: -55.2%
Depreciation and amortization
19.39M
Prev Year: 43.30M
YoY: -55.2%
Amortization
19.39M
Prev Year: 43.30M
YoY: -55.2%
Amortization of Intangibles
19.39M
Prev Year: 43.30M
YoY: -55.2%
Operating Income
409.50M
Prev Year: 474.20M
YoY: -13.6%
Net Non Operating Interest Income Expense
64.00M
Prev Year: 62.15M
YoY: +3.0%
Non-operating Interest Income
74.90M
Prev Year: 74.88M
YoY: +0.0%
Non-operating Interest Expense
10.90M
Prev Year: 12.34M
YoY: -11.7%
Other Income Expense
9.00M
Prev Year: 5.33M
YoY: +68.7%
Other Non-operating Income (expense)
9.00M
Prev Year: -4.67M
YoY: +292.7%
Equity in Earnings of Affiliates
-
Pre-tax Income
482.48M
Prev Year: 541.76M
YoY: -10.9%
Provision for Income Taxes
133.58M
Prev Year: 114.90M
YoY: +16.3%
Net Income Common Stockholders
348.90M
Prev Year: 426.86M
YoY: -18.3%
Net Income
348.90M
Prev Year: 426.86M
YoY: -18.3%
Net Income Including Non-Controlling Interests
348.90M
Prev Year: 426.86M
YoY: -18.3%
Net Income from Continuing Operations
348.90M
Prev Year: 426.86M
YoY: -18.3%
Basic EPS
1.82
Diluted EPS
1.8
Weighted Average Shares (basic)
191.79M
Weighted Average Shares (diluted)
197.39M
Net Income from Continuing and Discontinued Operation
348.90M
Prev Year: 426.86M
YoY: -18.3%
Normalized Income
348.90M
Prev Year: 418.98M
YoY: -16.7%
Interest Income
74.90M
Prev Year: 74.88M
YoY: +0.0%
Interest Expense
10.90M
Prev Year: 12.34M
YoY: -11.7%
Net Interest Income
64.00M
Prev Year: 62.15M
YoY: +3.0%
EBIT
493.38M
Prev Year: 554.10M
YoY: -11.0%
EBITDA
572.94M
Prev Year: 650.53M
YoY: -11.9%
Reconciled Cost of Revenue
657.27M
Prev Year: 527.11M
YoY: +24.7%
Reconciled Depreciation
79.56M
Prev Year: 96.43M
YoY: -17.5%
Net Income from Continuing Operation Net Minority Interest
348.90M
Prev Year: 426.86M
YoY: -18.3%
Normalized EBITDA
572.94M
Prev Year: 640.53M
YoY: -10.6%
Tax Rate for Calcs
0.277
Prev Year: 0
Values in USD

BioMarin Pharmaceutical key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$3.2B$2.9B$2.4B$2.1B$1.8B
Gross profit$2.5B$2.3B$1.9B$1.6B$1.4B
Operating income$409.5M$474.2M$185.8M$57.4M-$74.3M
Net income$348.9M$426.9M$167.6M$141.6M-$64.1M
Diluted EPS$1.80–$0.87$0.75-$0.35
Total assets$7.6B$7.0B$6.8B$6.4B$6.0B
Total liabilities$1.5B$1.3B$1.9B$1.8B$1.7B
Shareholders' equity$6.1B$5.7B$5.0B$4.6B$4.3B
Cash and short-term investments$1.6B$1.1B$1.1B$1.3B$1.0B
Total debt$605.9M$602.7M$1.1B$1.1B$1.1B
Operating cash flow$828.0M$572.8M$159.3M$175.9M$304.5M
Capital spending$111.0M$97.4M$107.6M$131.5M$119.2M
Free cash flow$717.0M$475.4M$51.6M$44.4M$185.3M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was BioMarin Pharmaceutical's revenue in fiscal year 2025?

$3.22 billion, up 12.9% from $2.85 billion in fiscal year 2024.

How much profit does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical reported net income of $348.90 million for fiscal year 2025 (10.8% of revenue); operating income was $409.50 million.

How much cash and debt does BioMarin Pharmaceutical have?

At the end of fiscal year 2025: cash and short-term investments of $1.56 billion and total debt of $605.86 million.

What is BioMarin Pharmaceutical's free cash flow?

$717.02 million in fiscal year 2025 (operating cash flow of $827.99 million minus capital spending of $110.98 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube